BRPI0519331A2 - formas cristalina de um inibidor de fator xa - Google Patents

formas cristalina de um inibidor de fator xa

Info

Publication number
BRPI0519331A2
BRPI0519331A2 BRPI0519331-1A BRPI0519331A BRPI0519331A2 BR PI0519331 A2 BRPI0519331 A2 BR PI0519331A2 BR PI0519331 A BRPI0519331 A BR PI0519331A BR PI0519331 A2 BRPI0519331 A2 BR PI0519331A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
factor inhibitor
pyridin
phenyl
pharmaceutical compositions
Prior art date
Application number
BRPI0519331-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael J Orwat
Mary F Malley
Roxana F Schlam
Steven R Fabian
Bing-Shiou Yang
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0519331A2 publication Critical patent/BRPI0519331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0519331-1A 2004-12-15 2005-12-14 formas cristalina de um inibidor de fator xa BRPI0519331A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18
PCT/US2005/045158 WO2006065853A2 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
BRPI0519331A2 true BRPI0519331A2 (pt) 2009-01-20

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519331-1A BRPI0519331A2 (pt) 2004-12-15 2005-12-14 formas cristalina de um inibidor de fator xa

Country Status (15)

Country Link
US (2) US7371864B2 (https=)
EP (1) EP1828187A2 (https=)
JP (1) JP2008524228A (https=)
KR (1) KR20070087606A (https=)
AR (1) AR053990A1 (https=)
AU (1) AU2005317158A1 (https=)
BR (1) BRPI0519331A2 (https=)
CA (1) CA2589886A1 (https=)
IL (1) IL183825A0 (https=)
MX (1) MX2007006919A (https=)
NO (1) NO20072666L (https=)
PE (1) PE20060739A1 (https=)
RU (1) RU2007126770A (https=)
TW (1) TW200634011A (https=)
WO (1) WO2006065853A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636756B2 (en) 2008-05-27 2019-11-20 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
EP2401396B1 (en) 2009-02-26 2016-11-23 Dako Denmark A/S Methods for performing a stringent wash step in hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
AR116951A1 (es) 2018-11-02 2021-06-30 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461202C (en) * 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7388096B2 (en) * 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones

Also Published As

Publication number Publication date
KR20070087606A (ko) 2007-08-28
WO2006065853A3 (en) 2006-08-24
AR053990A1 (es) 2007-05-30
NO20072666L (no) 2007-09-07
AU2005317158A1 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22
MX2007006919A (es) 2007-06-26
JP2008524228A (ja) 2008-07-10
RU2007126770A (ru) 2009-01-27
PE20060739A1 (es) 2006-08-16
US7371864B2 (en) 2008-05-13
IL183825A0 (en) 2007-09-20
EP1828187A2 (en) 2007-09-05
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
US20080188517A1 (en) 2008-08-07
WO2006065853A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2002078766A3 (en) Combination therapy
WO2007058850A3 (en) Inhibitors of akt activity
NO20082091L (no) Nye pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
MY152283A (en) Polo-like kinase inhibitirs
AP1767A (en) 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
WO2007117995A3 (en) Kinase inhibitors
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
ZA200306419B (en) Phenyl derivatives.
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
WO2009146218A8 (en) Compounds including an anti-inflammatory pharmacore and methods of use
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
WO2006071862A3 (en) Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
WO2008079814A3 (en) Mapk/erk kinase inhibitors
CA2520979A1 (en) Formulations of ecteinascidins
WO2006126081A3 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2008054956A3 (en) Kinase inhibitors
WO2004100890A3 (en) Rage g82s-related methods and compositions for treating inflammatory disorders
WO2007030618A3 (en) Bicyclic derivatives as modulators of voltage gated ion channels
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
NO20072666L (no) Krystallinske former av en faktor Xa-inhibitor
WO2008045834A3 (en) Kinase inhibitors
WO2007005962A3 (en) Combinations of eszopiclone and an antidepressant
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases
AU2002335027A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
UA91529C2 (en) Crystalline form of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2h-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one as a factor xa inhibitor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.